

**THE FUTURE OF
NUTRIGENOMICS**

**New opportunities in personalized
nutrition and food-pharma
collaboration**

By Dr Cheryl L Barton

Dr Cheryl L Barton

Dr Cheryl L Barton is an independent consultant with over 16 year's research and business analysis experience. Following her senior research positions in academia and seven years with Merck, in which she was responsible for research projects ranging from Alzheimer's disease to schizophrenia, Dr Barton joined Dutch investment bank ABN Amro NV as a senior equity analyst. At ABN Amro NV she was lead analyst on several pan-European companies, and assessed the potential impact of new drug development on European Stocks.

In 2002, Dr Barton founded a consulting business to provide independent, tailor-made, pharmaceutical thematic research to investment houses and pharmaceutical companies. The research reports combine independent scientific analysis with patient-based models to forecast the potential sales growth of key drugs in clinical development.

Copyright © 2010 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

The Future of Nutrigenomics

Executive summary	10	
Defining nutrigenomics	10	
Market drivers	11	
Collaborative nutrigenomic research & consortia	12	
Leading food & drinks companies: nutrigenomic strategies	13	
Leading nutrigenomic testing companies	14	
Opportunities: convergence of pharma & diagnostics	15	
Challenges: regulation, ethical & IP issues	16	
Conclusions	17	
Chapter 1	Defining nutrigenomics	20
Summary		20
Introduction		21
‘Omic technologies		23
Nutrigenomics and the food & drinks industry		26
Nutrigenomics & food products		28
Nutrigenomics & personalized nutrition		28
Report outline		29
Chapter 2	Market drivers	32
Summary		32
Introduction		33
Drivers for personalized nutrition		34
Healthy aging		34

Consumer demographics	36
Chronic non-communicable disease	38
Urbanization and the emerging markets	40
Global health economics	41
Conclusions on drivers for personalized nutrition	42

Chapter 3 Collaborative nutrigenomic research & consortia 46

Summary	46
Introduction	47
Nutrigenomic research consortia	47
Nutrigenomic research in the EU	49
The European Nutrigenomics Organization (NuGO)	49
DiOGenes	51
TI Food and Nutrition	51
Vision EpiFood Project	53
Canada Foundation for Innovation (CFI)	53
Public-private in age-related diseases	53
Nutrigenomic research in the US	55
Public-private partnership: genetically modified crops	57
Nutrigenomic research across the world	58
International Society of Nutrigenetics/Nutrigenomics (ISNN)	58
Conclusions	59

Chapter 4 Leading food & drinks companies: nutrigenomic strategies 62

Summary	62
Introduction	63
Ingredients manufacturers approach to nutrigenomics	64
BASF	64
Chr Hansen	66
DSM	69
Food manufacturers' approach to nutrigenomics	73
Group Danone	73
Nestlé	76
Unilever	78
Pharma industry M&A in consumer nutrition	80
The evolving open network model	82

Co-development opportunities	86	
Areas for market growth & time scales	88	
Conclusions	90	
Chapter 5	Leading nutrigenomic testing companies	94
Summary	94	
Introduction	95	
Market leaders	95	
23andme.com	97	
GeneLink	98	
Gene Smart	98	
Genova Diagnostics	99	
Interleukin Genetics Inc	100	
WellGen Inc.	102	
Conclusions	104	
Chapter 6	Opportunities: convergence of pharma & diagnostics	108
Summary	108	
Introduction	109	
Nutrigenomics vs pharmacogenomics	110	
Global health issues treatment vs prevention	115	
Convergence of the pharmaceutical & diagnostic market	116	
Conclusions	118	
Chapter 7	Challenges: regulation, ethical & IP issues	120
Summary	120	
Introduction	121	
Regulation of nutrigenomic foods	122	
Europe	123	
Japan	124	
Regulation of nutrigenomic tests	125	
Ethical issues	127	

Public awareness & perceptions	128
Intellectual Property	129
Conclusions	131

Chapter 8 Conclusions 134

Summary	134
The food & drinks market	135
Global genetic testing market	136
Market trends	136
Overall conclusions	137

Appendix 140

Primary research methodology	140
Acknowledgments	141
Glossary	142
Index	145
Bibliography	148
Endnotes	151

List of Figures

Figure 1.1:	Nutrigenetics and nutrigenomics	22
Figure 1.2:	The ‘omics technologies	24
Figure 1.3:	The functional genomic tool box	26
Figure 1.4:	Applications of nutrigenomics in the food chain	27
Figure 2.5:	Drivers for the food & drinks industry	33
Figure 2.6:	The ageing population a driver for personalized nutrition	35
Figure 2.7:	Personalized nutrition targeting consumer segments	36
Figure 2.8:	Population over 60: world and developed regions (1950-2050)	37
Figure 2.9:	Nutritional challenges – obesity & metabolic syndrome	38
Figure 2.10:	Growth in consumers in developing & emerging countries (2008-2018)	40
Figure 2.11:	Healthcare expenditure as a share of GDP (2006)	41
Figure 2.12:	Target population of nutrigenomic based products	43
Figure 4.13:	BASF approach to gene discovery	65
Figure 4.14:	DSMs sales growth targeting four emerging business areas	70
Figure 4.15:	DSMs R&D competencies	72
Figure 4.16:	An International and interdisciplinary network	75
Figure 4.17:	Diversify & de-risk through externalization	84
Figure 4.18:	Open network model	85
Figure 4.19:	Waves of nutrigenomic development	90
Figure 5.20:	WellGen’s nutrigenomic based discovery	103
Figure 6.21:	Nutrigenomics vs pharmacogenomics	111
Figure 6.22:	Relationship of drugs, disease, genes and gene products	113
Figure 8.23:	Health and nutrition market segments (2009)	135
Figure 8.24:	Nutrigenomic impact on personalized nutrition	139

List of Tables

Table 3.1:	European Consortia and Nutrigenomic Research Programs	50
Table 3.2:	Nutrigenomics Network Programs	55
Table 4.3:	Stakeholders in nutrigenomic research and personalized nutrition	63
Table 4.4:	Chr Hansen - strategic alliances & investments	67
Table 4.5:	Nestlé nutrigenomic alliances & investments	77
Table 4.6:	Divestment of Animal, Consumer & Medical Nutrition Divisions	80
Table 4.7:	Consumer Health Divisions of Pharmaceutical Companies	81
Table 4.8:	Alliance between Food, Pharma, Biotech and the Diagnostic Industries	82
Table 5.9:	Categorization of genetic variations that may be included in nutrigenomic tests	96
Table 5.10:	Categorization of genetic variations that may be included in nutrigenomic tests	97
Table 6.11:	Known diet- gene interactions	112
Table 6.12:	Known gene-nutrient interactions	114

